Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)


You May Also Like

FIT Biotech Oy: FIT Biotech Ltd’s own equity negative in the end of November

FIT Biotech OyCompany release December 19, 2017 at 3 pm EET            DRAFT                      FIT Biotech Ltd's ...